• Citer

p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.

par Di Leo, Angelo ;Tanner, M;Desmedt, Christine ;Paesmans, Marianne ;Cardoso, Fatima ;Durbecq, Virginie ;Chan, S;Perren, Thimothy J.;Aapro, Matty;Sotiriou, Christos ;Piccart-Gebhart, Martine ;Larsimont, Denis ;Isola, Jorma;TAX 303 translational study team,
Référence Annals of oncology, 18, 6, page (997-1003)
Publication Publié, 2007-06

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.
Auteur:	Di Leo, Angelo; Tanner, M; Desmedt, Christine; Paesmans, Marianne; Cardoso, Fatima; Durbecq, Virginie; Chan, S; Perren, Thimothy J.; Aapro, Matty; Sotiriou, Christos; Piccart-Gebhart, Martine; Larsimont, Denis; Isola, Jorma; TAX 303 translational study team,
Informations sur la publication:	Annals of oncology, 18, 6, page (997-1003)
Statut de publication:	Publié, 2007-06
Sujet CREF:	Sciences bio-médicales et agricoles
	Cancérologie
	Médecine pathologie humaine
Mots-clés:	Cytotoxics
	Molecular markers
	Topoisomerase II alpha
MeSH keywords:	Antineoplastic Agents -- therapeutic use
	Breast Neoplasms -- drug therapy
	Breast Neoplasms -- genetics
	Breast Neoplasms -- pathology
	Chromatography, High Pressure Liquid
	DNA Primers
	DNA, Neoplasm -- genetics
	DNA, Neoplasm -- isolation & purification
	Doxorubicin -- therapeutic use
	Genes, p53
	Mutation
	Predictive Value of Tests
	Probability
	Protein Biosynthesis
	Taxoids -- therapeutic use
Note générale:	Clinical Trial, Phase III
	Journal Article
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdm075
	info:pii/mdm075
	info:scp/34447314153
	info:pmid/17369602